EDITORIAL
Published on 05 Nov 2024
Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines
doi 10.3389/fphar.2024.1490853
- 549 views
- Frontiers in Pharmacology
- Drugs Outcomes Research and Policies
- Research Topics
- Towards continued and affordable accessibility of innovative drugs: Sustainable development and efficient use of medicines
Towards continued and affordable accessibility of innovative drugs: Sustainable development and efficient use of medicines
8,300
Total downloads
35k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 24 Jun 2024
Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review
doi 10.3389/fphar.2024.1298923
- 1,630 views
ORIGINAL RESEARCH
Published on 10 Jun 2024
Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives
doi 10.3389/fphar.2024.1256992
- 840 views
REVIEW
Published on 28 Mar 2024
Dose reduction of biologics in patients with plaque psoriasis: a review
doi 10.3389/fphar.2024.1369805
- 2,249 views
ORIGINAL RESEARCH
Published on 14 Feb 2024
The impact of level of documentation on the accessibility and affordability of new drugs in Norway
doi 10.3389/fphar.2024.1338541
- 1,527 views
- 1 citation
ORIGINAL RESEARCH
Published on 29 Jan 2024
Ethics of access to newly approved expensive medical treatments: multi-stakeholder dialogues in a publicly funded healthcare system
doi 10.3389/fphar.2023.1265029
- 1,578 views
ORIGINAL RESEARCH
Published on 28 Nov 2023
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries
doi 10.3389/fphar.2023.1199500
- 6,271 views
- 4 citations
PERSPECTIVE
Published on 28 Nov 2023
Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer
doi 10.3389/fphar.2023.1274532
- 1,600 views
- 1 citation
ORIGINAL RESEARCH
Published on 17 Oct 2023
Product development and quality of pharmacy compounded chenodeoxycholic acid capsules for Dutch cerebrotendinous xanthomatosis patients
doi 10.3389/fphar.2023.1264997
- 1,260 views
ORIGINAL RESEARCH
Published on 07 Sep 2023
Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
doi 10.3389/fphar.2023.1219694
- 1,316 views
- 3 citations
ORIGINAL RESEARCH
Published on 31 Aug 2023
Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
doi 10.3389/fphar.2023.1238009
- 2,526 views
- 2 citations
ORIGINAL RESEARCH
Published on 31 Aug 2023
Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
doi 10.3389/fimmu.2023.1223020
- 1,916 views
- 4 citations
Published in
Frontiers in Pharmacology
- Drugs Outcomes Research and Policies
Participating Journals
Frontiers in Immunology
- 5.7 impact factor
- 9.8 citescore
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Impact
- 35kTopic views
- 26kArticle views
- 8,300Article downloads